OncoHost gains New York State Laboratory Permit for PROphetNSCLC test
OncoHost has received a laboratory permit from New York State, enabling the distribution of its PROphetNSCLC test to physicians and patients statewide, enhancing personalized treatment options for lung cancer.
OncoHost announced that it has received a laboratory permit from the New York State Department of Health Wadsworth Center. This permit enables the company to offer its PROphetNSCLC test to physicians and patients across New York State.
PROphet, OncoHost’s AI-powered proteomic profiling platform, is designed to guide first-line treatment decisions in oncology. Its proprietary test, PROphetNSCLC, has been commercially available since 2023 and supports oncologists treating patients with metastatic non-small cell lung cancer (mNSCLC). Using a single blood sample, the test analyzes thousands of plasma proteins to generate a personalized probability of clinical benefit from PD-1/PD-L1 inhibitors - empowering physicians to optimize treatment selection and improve patient outcomes.
The New York permit joins OncoHost’s existing certifications under the Clinical Laboratory Improvement Amendments (CLIA) and its accreditation by the College of American Pathologists (CAP).
With this latest regulatory achievement, PROphetNSCLC is now officially available for clinical use in all 50 U.S. states.
